Benefit/risk profile of dapagliflozin 5 mg in the
DEPICT
‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m
2
Diabetes, Obesity and Metabolism(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要